咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Epidemiology, clinical charact... 收藏

Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome

作     者:Jia-Chen Li Jing Zhao Hao Li Li-Qun Fang Wei Liu Jia-Chen Li;Jing Zhao;Hao Li;Li-Qun Fang;Wei Liu

作者机构:State Key Laboratory of Pathogen and BiosecurityBeijing Institute of Microbiology and EpidemiologyBeijing100071China 

出 版 物:《Infectious Medicine》 (感染医学(英文))

年 卷 期:2022年第1卷第1期

页      面:40-49页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基  金:This work was supported by grants from the National Science Fund for Distinguished Young Scholars(No.81825019) the National Key Research and Develop-ment Plan of China(No.2021YFC2300200-02) the China Mega-Project on Infectious Disease Prevention(No.2018ZX10713002) 

主  题:SFTS Epidemiology Transmission Risk factors Treatment 

摘      要:Severe fever with thrombocytopenia syndrome(SFTS)is an emerging tick-borne infectious disease caused by a novel phlebovirus(SFTS virus,SFTSV)in the family Phenuiviridae of the order *** disease causes a wide spectrum of clinical signs and symptoms,ranging from mild febrile disease accompanied by thrombocy-topenia and/or leukocytopenia to hemorrhagic fever,encephalitis,multiple organ failure,and *** was first identified in China and was subsequently reported in South Korea and *** case-fatality rate ranges from 2.7%to 45.7%.Older age has been consistently shown to be the most important predictor of adverse disease *** age exacerbates disease mainly through dysregulation of host immune cells and uncontrolled inflammatory ***-to-human transmission is the primary route of human infection with SFTSV,and Haemaphysalis longicornis is the primary tick vector of *** its high case-fatality rate,vaccines and an-tiviral therapies for SFTS are not currently *** therapeutic efficacies of several antiviral agents against SFTSV are currently being *** was initially identified as a potential antiviral therapy for SFTS but was subsequently found to inefficiently improve disease outcomes,especially among patients with high viral ***(T705)decreased both time to clinical improvement and mortality when administered early in patients with low viral ***-inflammatory agents including corticosteroids have been proposed to play therapeutic ***,the efficacy of other therapeutic modalities,such as convalescent plasma,is not yet clear.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分